Foghorn Therapeutics Inc.
FHTX
$6.26
-$0.23-3.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.98% | 20.08% | 36.75% | -3.91% | -31.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.98% | 20.08% | 36.75% | -3.91% | -31.30% |
| Cost of Revenue | -11.04% | -9.40% | -9.59% | -14.56% | -11.20% |
| Gross Profit | 34.68% | 19.73% | 24.15% | 18.29% | 0.25% |
| SG&A Expenses | -3.80% | -3.57% | -2.85% | -6.62% | -9.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.33% | -8.03% | -8.03% | -12.75% | -10.84% |
| Operating Income | 25.46% | 14.99% | 18.13% | 14.96% | 3.26% |
| Income Before Tax | 14.35% | 6.36% | 14.24% | 19.18% | 9.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.35% | 6.36% | 14.24% | 20.94% | 12.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.35% | 6.36% | 14.24% | 20.94% | 12.78% |
| EBIT | 25.46% | 14.99% | 18.13% | 14.96% | 3.26% |
| EBITDA | 25.19% | 15.09% | 18.93% | 15.53% | 3.20% |
| EPS Basic | 18.12% | 14.34% | 28.55% | 40.03% | 38.37% |
| Normalized Basic EPS | 23.78% | 16.48% | 30.71% | 36.95% | 34.64% |
| EPS Diluted | 18.12% | 14.34% | 28.55% | 40.03% | 38.37% |
| Normalized Diluted EPS | 23.78% | 16.48% | 30.71% | 36.95% | 34.64% |
| Average Basic Shares Outstanding | 5.95% | 7.80% | 14.78% | 26.60% | 40.97% |
| Average Diluted Shares Outstanding | 5.95% | 7.80% | 14.78% | 26.60% | 40.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |